Earnings Forecast Research on Evoke Pharma, Inc. (EVOK)

Evoke Pharma, Inc. has received $-0.17 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.22 while the top line estimate is $-0.13 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 55.41%.

Evoke Pharma, Inc. reported better than expected with a surprise EPS of 11.11% or $0.03 during its most recent quarterly earnings. The Actual EPS was $-0.24 compared to the Estimated EPS of $-0.27.

In the last quarter, Evoke Pharma, Inc. reported Annual Earnings of $-0.24. Based on the filings, last years Annual Earnings was, $-1.87. In the last Quarter, EVOK reported a surprise Earnings per Share of 11.11% . The consensus estimate for current quarter is $-0.17 and for the current fiscal year, the estimate is $-1.21. For the Next fiscal year, the estimate is $-0.59 based on the consensus.

Evoke Pharma, Inc. (NASDAQ:EVOK) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.04 points or 1.4% at $2.81 with 1,650,795 shares getting traded. Post opening the session at $2.9, the shares hit an intraday low of $2.72 and an intraday high of $3.15 and the price was in this range throughout the day. The company has a market cap of $35 million and the number of outstanding shares has been calculated to be 12,350,360 shares. The 52-week high of Evoke Pharma, Inc. (NASDAQ:EVOK) is $11.11 and the 52-week low is $1.35.

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Companys lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.


Share this post

Leave a Reply